Moderna will request authorization for the emergency use of the vaccine in the US and Europe on Monday

Early Data Show Moderna’s Coronavirus Vaccine Is 94.5% Effective

Early Data Show Moderna’s Coronavirus Vaccine Is 94.5% Effective

Moderna Inc said it will request authorization for emergency use in the United States and the European Union of its COVID-19 vaccine on Monday, based on the full results of the latest phase of a study that showed that their vaccine is 94.1% effective, without serious safety concerns.

Moderna also reported an efficacy rate consistent with race, age, ethnicity, and gender and indicated that its vaccine was 100% capable of preventing severe symptoms from COVID-19, the disease that has killed 1, 5 million people in the world.

The procedure will leave Moderna as the second company in line to receive authorization for the emergency use of its vaccine this year in the United States, after the formula developed by Pfizer (NYSE: PFE ) and BioNTech will be 95% effective. in clinical trials.

“We thought we had a highly effective vaccine. Now we have the data to prove it,” Ral Zaks, the firm’s chief medical officer, said in a telephone interview. “We hope to play an important role in defeating this pandemic.”

Zaks said he was excited to see the 94.1% result over the weekend: “It’s the first time I’ve allowed myself to cry. With this level of effectiveness, when you do the math on what this means for the pandemic that It surrounds us, it’s just overwhelming. “

Of the 196 volunteers who became infected with COVID-19 in the trial with more than 300,000 people, 185 had received a placebo and only 11 the vaccine. Moderna reported 30 severe cases of the coronavirus – all in the placebo group – which means that the formula is 100% effective in preventing severe symptoms of COVID-19.

“As the numbers of coronavirus in the world increase, so is confidence in the incredible level of protection that a product can offer to the population,” said Alexander Edwards, associate professor of biomedical technology at the University of Reading in the United Kingdom. .

In addition to the application in the United States, Moderna will request conditional approval for its vaccine from the European Medicines Agency (EMA), which has already begun to review the data. The company said it would also contact other health regulators.

Pfizer has already requested approval for emergency use of its vaccine in the United States and Europe, which is one week ahead of Moderna.

Moderna said it was on track to have about 20 million doses of its vaccine ready for distribution in the United States by the end of 2020, enough to inoculate 10 million people.

Pfizer's vaccine will be available in UK next week

Pfizer's vaccine will be available in UK next week The UK has become the first Western country to approve a Read more

Pfizer's coronavirus vaccine sparks optimism

Pfizer's coronavirus vaccine sparks optimism. The European Commission announced this Wednesday an agreement reached with the pharmaceutical firms Pfizer and Read more

Pfizer’s late-stage coronavirus vaccine trial is near complete

Pfizer’s late-stage coronavirus vaccine trial is near complete. The countdown to the arrival of the Covid vaccine has begun. Pfizer Read more

45 vaccine candidates in human trials

45 vaccine candidates in human trials. Governments, companies, health systems and citizens scrutinize with great interest to know when a Read more

Moderna prepares for the "commercial launch" of its vaccine

Moderna prepares for the "commercial launch" of its vaccine. Modern biotechnology begins the procedures to request the authorization of its Read more

Moderna claims its COVID-19 vaccine produces a "robust" immune response

Moderna claims its COVID-19 vaccine produces a "robust" immune response. Scientists around the world will continue to search for a Read more

US Quickly Seeks COVID-19 Vaccine

US Quickly Seeks COVID-19 Vaccine. "Phase 1 of the clinical trial to evaluate an investigational vaccine designed for coronavirus disease Read more

Grifols starts the trial to test its immunoglobulin in patients with Covid-19

Grifols starts the trial to test its immunoglobulin in patients with Covid-19. Grifols has announced the start of the clinical Read more

The European Union approves extraordinary funds of 750 billion for recovery after the pandemic

The European Union approves extraordinary funds of 750 billion for recovery after the pandemic.   With a «We did it! Read more

CytoDyn rejected by the FDA

CytoDyn rejected by the FDA. The FDA rejected CytoDyn’s application for its lead program, an antibody to treat HIV in Read more

Leave a Reply